Search Results

You are looking at 1 - 10 of 207 items for :

  • "cytogenetics" x
Clear All
Full access

Alison R. Walker and Guido Marcucci

difficult to similarly define risk in patients with cytogenetically normal (CN) AML. However, with the discovery of recurrent somatic mutations, patients with CN-AML are now categorized into molecularly defined subgroups with distinct clinical outcomes. The

Full access

Jill Corre and Hervé Avet-Loiseau

cytogenetics have identified recurrent chromosomal changes and correlated these with clinical outcomes ( Table 1 ). Abnormalities such as t(4;14) and t(14;16), and loss of 17p13 confer a poor prognosis in patients undergoing high-dose therapy. In contrast

Full access

Mark G. Frattini and Peter G. Maslak

Edited by Kerrin G. Robinson

myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subtypes with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study . Blood 1997 ; 89 : 3323 – 3329

Full access

Wei Wang, Guilin Tang, Tapan Kadia, Xinyan Lu, Yan Li, Lanshan Huang, Ximena Montenegro-Garreaud, Roberto N. Miranda and Sa A. Wang

cytogenetic evolution with the development of additional genetic abnormalities may be one of the mechanisms mediating disease progression and transformation. Case Report A 55-year-old woman presented with 48 × 10 9 /L WBCs and 22% circulating blasts

Full access

Holbrook E. Kohrt and Steven E. Coutre

Godwin J . Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study . Blood 1997

Full access

Margaret R. O’Donnell

“In the majority of our patients, the major risk factor for whether they will do well or poorly is related to their cytogenetic and/or molecular markers,” stated Margaret R. O’Donnell, MD, Associate Clinical Director, Division of Hematology and

Full access

David D. Stenehjem, Frederick Albright, Kuan-Ling Kuo, Karina Raimundo, Hillevi Bauer, Paul J. Shami, Michael W. Deininger, Lei Chen and Diana I. Brixner

-α combined with low-dose cytarabine. 1 According to the 5-year follow-up of the IRIS trial, imatinib used as initial therapy produced a cumulative complete cytogenetic response (CCyR) rate of 87%. 1 , 2 The 8-year follow-up, presented in abstract form only

Full access

Michael E O'Dwyer

trials: Chronic Myeloid Leukemia Trialists' Collaborative Group . J Natl Cancer Inst 1997 ; 89 : 1616 – 1620 . 11 Bonifazi F de Vivo A Rosti G . Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

Full access

Margaret R. O'Donnell, Camille N. Abboud, Jessica Altman, Frederick R. Appelbaum, Steven E. Coutre, Lloyd E. Damon, James M. Foran, Salil Goorha, Lori J. Maness, Guido Marcucci, Peter Maslak, Michael M. Millenson, Joseph O. Moore, Farhad Ravandi, Paul J. Shami, B. Douglas Smith, Richard M. Stone, Stephen A. Strickland, Martin S. Tallman and Eunice S. Wang

-T). In addition, WHO allows AML to be diagnosed regardless of the percentage of marrow blasts in patients with abnormal hematopoiesis and characteristic clonal structural cytogenetic abnormalities, including t(15;17), t(8;21), and inv(16) or t(16

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

and survival in myeloma patients with metaphase cytogenetic abnormalities . Blood 2008 ; 112 : 3115 – 3121 . 43 Morgan GJ Jackson GH Davies FE . Maintenance thalidomide may improve progression free but not overall survival; results from